Wake Forest University Baptist Medical Center has become the first medical center to use the GliaSite Radiation Therapy System, a device that delivers high doses of radiation directly into tumor tissue. This innovation aims to improve treatment outcomes for patients with malignant brain tumors.
Researchers at Penn State's College of Medicine have identified a marker for certain types of brain tumors, including glioblastoma multiforme (GBM), which are the most prevalent and difficult-to-manage. The marker, interleukin 13 receptor, is present in over 90% of patients with GBM, making it a valuable diagnostic tool.
The Pediatric Brain Tumor Consortium, sponsored by the National Cancer Institute, aims to speed the development of innovative treatments for children with brain tumors. The consortium brings together experts from eight institutions to conceive, develop and carry out pilot studies and early trials of promising new therapies.
A study of 203 children with medulloblastoma found that a tried-and-true chemotherapy protocol provides better results than a newer method, while the quality of neurosurgery also affects long-term survival rates. The ability to remove nearly all of the tumor is critical for improved outcomes.
Researchers at Johns Hopkins University have linked specific gene mutations to the growth of fatal brain tumors in flies, mirroring human cancer progression. The study's findings suggest that a key signaling pathway may be responsible for tumor growth, offering potential new avenues for cancer treatment.
The US Department of Energy's Brookhaven National Laboratory is offering a new clinical trial for brain tumor patients, including those whose cancer is inoperable or has regrown. The trial aims to increase the radiation dose and expand eligibility requirements for glioblastoma multiforme patients.
Researchers discovered specific genetic changes that indicate whether chemotherapy is effective in treating patients with anaplastic oligodendrogliomas. The discovery allows for immediate determination of chemotherapy response at diagnosis, offering improved treatment options for patients.
Researchers have discovered a gene called E2F1 that helps bring about tumor cell death yet is also necessary for their growth. The study found that without E2F1, tumors grew slower but cell death was reduced by 80 percent.
Squalamine, a novel liver steroid, has been shown to inhibit the growth of brain tumors called gliomas by disabling blood vessel formation. In laboratory tests, it proved as effective as carmustine in slowing tumor growth and constricting blood vessels, suggesting potential as a human therapy.
A recent study found that brain-enriched hyaluronan binding protein (BEHAB) is a key factor in brain cancer cells' ability to invade healthy tissue. Researchers hope to develop therapies that block BEHAB's function or reduce its production, potentially slowing tumor progression.
Scientists at NIH developed a new drug that reduces tumor size without severe side effects. In a clinical trial, 9 of 15 patients had significant tumor regression, with complete disappearance in two cases. A related therapy using virus-producing cells also showed promise, but only for small tumors.
Researchers at St. Jude Children's Research Hospital are developing new brain tumor treatment protocols that use 3D imaging to accurately target tumors, reducing radiation doses and side effects. The protocols involve combining lower-dose radiation with chemotherapy to increase survival rates and minimize long-term damage.
Scientists activate protein receptor to stimulate cell death in brain tumors, potentially sparing normal brain tissue. The therapy shows promise in treating nearly untreatable primary central nervous system lymphomas.
A new study reveals that transcranial sonography is more sensitive than MRI and CT in detecting residual tumors and predicting patient survival after brain tumor surgery. This non-invasive imaging technique offers advantages, including lower cost, portability, and ease of use, making it a valuable tool for follow-up care.
Researchers found glioblastoma multiforme tumors resistant to procarbazine exhibited defects in mismatch repair, leading to drug resistance. The study may lead to more effective treatment of GBM, a common and virulent brain tumor.
A new vaccine has shown promise in treating brain tumors by boosting the immune system. The study found that GM-CSF produced a powerful anti-tumor effect, with 15% of mice appearing cured of pre-established tumors. The researchers believe this strategy may provide a potent double hit on aggressive brain tumors.
Researchers at Johns Hopkins Medicine found that squalamine, a shark liver substance, nearly stops the growth of new blood vessels that nourish solid brain tumors. The study showed a significant reduction in tumor cell growth and slowed the formation of new blood vessels by up to 83% after two days.